Rani Therapeutics Holdings, Inc. Overview
Pro stress-test →Rani Therapeutics is a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs. The company has developed the RaniPill® capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing.
Strategic Profile
Pro stress-test →Rani is advancing a Phase 1 clinical trial evaluating RT-114 for obesity treatment in collaboration with ProGen. The company is in early-stage development with losses narrowing year-over-year, and recently secured capital through an at-the-market offering in May 2026 to extend runway and evaluate pipeline opportunities.
Competitive Landscape
Pro stress-test →Rani competes in oral biologics delivery, a nascent but growing space targeting the large injectable drug market. Direct competitors include Biolex Therapeutics (acquired by Merck), Rani's focus on obesity via RT-114 places it in competition with GLP-1 players (Novo Nordisk, Eli Lilly) and oral alternative developers. Its proprietary RaniPill® platform differentiates on the technical delivery mechanism, though clinical validation is still pending.
Industry Context
Rani Therapeutics Holdings, Inc. operates in Biopharmaceutical Drug Delivery.
Key facts
Founded: 2017 · Headquarters: SAN JOSE, US · Employees: N/A · Revenue: $0 · Market cap: N/A